Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 108

1.

Functional characterization of AC5 gain-of-function variants: Impact on the molecular basis of ADCY5-related dyskinesia.

Doyle TB, Hayes MP, Chen DH, Raskind WH, Watts VJ.

Biochem Pharmacol. 2019 May;163:169-177. doi: 10.1016/j.bcp.2019.02.005. Epub 2019 Feb 14.

PMID:
30772269
2.

Insights into the Regulatory Properties of Human Adenylyl Cyclase Type 9.

Baldwin TA, Li Y, Brand CS, Watts VJ, Dessauer CW.

Mol Pharmacol. 2019 Apr;95(4):349-360. doi: 10.1124/mol.118.114595. Epub 2019 Jan 29.

PMID:
30696718
3.

Genomics, GPCRs and new targets for the control of insect pests and vectors.

Hill CA, Sharan S, Watts VJ.

Curr Opin Insect Sci. 2018 Dec;30:99-106. doi: 10.1016/j.cois.2018.08.010. Epub 2018 Aug 30. Review.

PMID:
30553493
4.

Optimization of a 1,3,4-oxadiazole series for inhibition of Ca2+/calmodulin-stimulated activity of adenylyl cyclases 1 and 8 for the treatment of chronic pain.

Kaur J, Soto-Velasquez M, Ding Z, Ghanbarpour A, Lill MA, van Rijn RM, Watts VJ, Flaherty DP.

Eur J Med Chem. 2019 Jan 15;162:568-585. doi: 10.1016/j.ejmech.2018.11.036. Epub 2018 Nov 16.

PMID:
30472604
5.

Nucleobase Modified Adefovir (PMEA) Analogues as Potent and Selective Inhibitors of Adenylate Cyclases from Bordetella pertussis and Bacillus anthracis.

Česnek M, Skácel J, Jansa P, Dračínský M, Šmídková M, Mertlíková-Kaiserová H, Soto-Velasquez MP, Watts VJ, Janeba Z.

ChemMedChem. 2018 Sep 6;13(17):1779-1796. doi: 10.1002/cmdc.201800332. Epub 2018 Jul 31.

6.

A Novel CRISPR/Cas9-Based Cellular Model to Explore Adenylyl Cyclase and cAMP Signaling.

Soto-Velasquez M, Hayes MP, Alpsoy A, Dykhuizen EC, Watts VJ.

Mol Pharmacol. 2018 Sep;94(3):963-972. doi: 10.1124/mol.118.111849. Epub 2018 Jun 27.

7.

Synthesis of α-Branched Acyclic Nucleoside Phosphonates as Potential Inhibitors of Bacterial Adenylate Cyclases.

Frydrych J, Skácel J, Šmídková M, Mertlíková-Kaiserová H, Dračínský M, Gnanasekaran R, Lepšík M, Soto-Velasquez M, Watts VJ, Janeba Z.

ChemMedChem. 2018 Jan 22;13(2):199-206. doi: 10.1002/cmdc.201700715. Epub 2018 Jan 8.

PMID:
29235265
8.

Selective Adenylyl Cyclase Type 1 Inhibitors as Potential Opioid Alternatives For Chronic Pain.

Watts VJ.

Neuropsychopharmacology. 2018 Jan;43(1):215-216. doi: 10.1038/npp.2017.190. No abstract available.

9.

Identification of FDA-Approved Small Molecules Capable of Disrupting the Calmodulin-Adenylyl Cyclase 8 Interaction through Direct Binding to Calmodulin.

Hayes MP, Soto-Velasquez M, Fowler CA, Watts VJ, Roman DL.

ACS Chem Neurosci. 2018 Feb 21;9(2):346-357. doi: 10.1021/acschemneuro.7b00349. Epub 2017 Oct 16.

10.

International Union of Basic and Clinical Pharmacology. CI. Structures and Small Molecule Modulators of Mammalian Adenylyl Cyclases.

Dessauer CW, Watts VJ, Ostrom RS, Conti M, Dove S, Seifert R.

Pharmacol Rev. 2017 Apr;69(2):93-139. doi: 10.1124/pr.116.013078. Review.

11.

Identification of a selective small-molecule inhibitor of type 1 adenylyl cyclase activity with analgesic properties.

Brust TF, Alongkronrusmee D, Soto-Velasquez M, Baldwin TA, Ye Z, Dai M, Dessauer CW, van Rijn RM, Watts VJ.

Sci Signal. 2017 Feb 21;10(467). pii: eaah5381. doi: 10.1126/scisignal.aah5381.

12.

Molecular Modeling Evaluation of the Enantiomers of a Novel Adenylyl Cyclase 2 Inhibitor.

Rana N, Conley JM, Soto-Velasquez M, León F, Cutler SJ, Watts VJ, Lill MA.

J Chem Inf Model. 2017 Feb 27;57(2):322-334. doi: 10.1021/acs.jcim.6b00454. Epub 2017 Jan 26.

PMID:
28068084
13.

Design and Synthesis of Fluorescent Acyclic Nucleoside Phosphonates as Potent Inhibitors of Bacterial Adenylate Cyclases.

Břehová P, Šmídková M, Skácel J, Dračínský M, Mertlíková-Kaiserová H, Velasquez MP, Watts VJ, Janeba Z.

ChemMedChem. 2016 Nov 21;11(22):2534-2546. doi: 10.1002/cmdc.201600439. Epub 2016 Oct 24.

14.

[Research progress of Gα(i/o)-coupled receptor-mediated supersensitization of adenylyl cyclase].

Xu RQ, Watts VJ.

Yao Xue Xue Bao. 2016 Sep;51(9):1349-55. Review. Chinese.

PMID:
29924508
15.
16.

Bisamidate Prodrugs of 2-Substituted 9-[2-(Phosphonomethoxy)ethyl]adenine (PMEA, adefovir) as Selective Inhibitors of Adenylate Cyclase Toxin from Bordetella pertussis.

Česnek M, Jansa P, Šmídková M, Mertlíková-Kaiserová H, Dračínský M, Brust TF, Pávek P, Trejtnar F, Watts VJ, Janeba Z.

ChemMedChem. 2015 Aug;10(8):1351-64. doi: 10.1002/cmdc.201500183. Epub 2015 Jul 1.

PMID:
26136378
17.

Gα(i/o)-coupled receptor-mediated sensitization of adenylyl cyclase: 40 years later.

Brust TF, Conley JM, Watts VJ.

Eur J Pharmacol. 2015 Sep 15;763(Pt B):223-32. doi: 10.1016/j.ejphar.2015.05.014. Epub 2015 May 14. Review.

18.

Dopamine receptor antagonists as new mode-of-action insecticide leads for control of Aedes and Culex mosquito vectors.

Nuss AB, Ejendal KF, Doyle TB, Meyer JM, Lang EG, Watts VJ, Hill CA.

PLoS Negl Trop Dis. 2015 Mar 20;9(3):e0003515. doi: 10.1371/journal.pntd.0003515. eCollection 2015 Mar.

19.

Palladium-catalyzed regio- and stereoselective γ-arylation of tertiary allylic amines: identification of potent adenylyl cyclase inhibitors.

Ye Z, Brust TF, Watts VJ, Dai M.

Org Lett. 2015 Feb 20;17(4):892-5. doi: 10.1021/ol503748t. Epub 2015 Feb 10.

20.

Bias analyses of preclinical and clinical D2 dopamine ligands: studies with immediate and complex signaling pathways.

Brust TF, Hayes MP, Roman DL, Burris KD, Watts VJ.

J Pharmacol Exp Ther. 2015 Mar;352(3):480-93. doi: 10.1124/jpet.114.220293. Epub 2014 Dec 24.

21.

New functional activity of aripiprazole revealed: Robust antagonism of D2 dopamine receptor-stimulated Gβγ signaling.

Brust TF, Hayes MP, Roman DL, Watts VJ.

Biochem Pharmacol. 2015 Jan 1;93(1):85-91. doi: 10.1016/j.bcp.2014.10.014. Epub 2014 Nov 7.

22.

Evaluation of AaDOP2 receptor antagonists reveals antidepressants and antipsychotics as novel lead molecules for control of the yellow fever mosquito, Aedes aegypti.

Conley JM, Meyer JM, Nuss AB, Doyle TB, Savinov SN, Hill CA, Watts VJ.

J Pharmacol Exp Ther. 2015 Jan;352(1):53-60. doi: 10.1124/jpet.114.219717. Epub 2014 Oct 20.

23.

(-)-Stepholidine is a potent pan-dopamine receptor antagonist of both G protein- and β-arrestin-mediated signaling.

Meade JA, Free RB, Miller NR, Chun LS, Doyle TB, Moritz AE, Conroy JL, Watts VJ, Sibley DR.

Psychopharmacology (Berl). 2015 Mar;232(5):917-30. doi: 10.1007/s00213-014-3726-8. Epub 2014 Sep 18.

24.

Polydopamine-based simple and versatile surface modification of polymeric nano drug carriers.

Park J, Brust TF, Lee HJ, Lee SC, Watts VJ, Yeo Y.

ACS Nano. 2014 Apr 22;8(4):3347-56. doi: 10.1021/nn405809c. Epub 2014 Mar 19.

25.

Drug-induced sensitization of adenylyl cyclase: assay streamlining and miniaturization for small molecule and siRNA screening applications.

Conley JM, Brust TF, Xu R, Burris KD, Watts VJ.

J Vis Exp. 2014 Jan 27;(83):e51218. doi: 10.3791/51218.

26.

Development of a high-throughput screening paradigm for the discovery of small-molecule modulators of adenylyl cyclase: identification of an adenylyl cyclase 2 inhibitor.

Conley JM, Brand CS, Bogard AS, Pratt EP, Xu R, Hockerman GH, Ostrom RS, Dessauer CW, Watts VJ.

J Pharmacol Exp Ther. 2013 Nov;347(2):276-87. doi: 10.1124/jpet.113.207449. Epub 2013 Sep 5.

27.

Cell-type specific increases in female hamster nucleus accumbens spine density following female sexual experience.

Staffend NA, Hedges VL, Chemel BR, Watts VJ, Meisel RL.

Brain Struct Funct. 2014 Nov;219(6):2071-81. doi: 10.1007/s00429-013-0624-5. Epub 2013 Aug 11.

28.

Differential effects of AGS3 expression on D(2L) dopamine receptor-mediated adenylyl cyclase signaling.

Conley JM, Watts VJ.

Cell Mol Neurobiol. 2013 May;33(4):551-8. doi: 10.1007/s10571-013-9925-8. Epub 2013 Mar 17.

29.

Bimolecular fluorescence complementation analysis of G protein-coupled receptor dimerization in living cells.

Ejendal KF, Conley JM, Hu CD, Watts VJ.

Methods Enzymol. 2013;521:259-79. doi: 10.1016/B978-0-12-391862-8.00014-4.

PMID:
23351744
30.

Discovery of antagonists of tick dopamine receptors via chemical library screening and comparative pharmacological analyses.

Ejendal KF, Meyer JM, Brust TF, Avramova LV, Hill CA, Watts VJ.

Insect Biochem Mol Biol. 2012 Nov;42(11):846-53.

PMID:
23213654
31.

Identification of a 2-phenyl-substituted octahydrobenzo[f]quinoline as a dopamine D₃ receptor-selective full agonist ligand.

Clark AH, McCorvy JD, Conley JM, Williams WK, Bekkam M, Watts VJ, Nichols DE.

Bioorg Med Chem. 2012 Nov 1;20(21):6366-74. doi: 10.1016/j.bmc.2012.08.058. Epub 2012 Sep 8.

32.

Dopamine D(2) Receptor-Mediated Heterologous Sensitization of AC5 Requires Signalosome Assembly.

Ejendal KF, Dessauer CW, Hébert TE, Watts VJ.

J Signal Transduct. 2012;2012:210324. doi: 10.1155/2012/210324. Epub 2012 Mar 12.

33.

Ligand-specific roles for transmembrane 5 serine residues in the binding and efficacy of dopamine D(1) receptor catechol agonists.

Chemel BR, Bonner LA, Watts VJ, Nichols DE.

Mol Pharmacol. 2012 May;81(5):729-38. doi: 10.1124/mol.111.077339. Epub 2012 Feb 14.

34.

A "genome-to-lead" approach for insecticide discovery: pharmacological characterization and screening of Aedes aegypti D(1)-like dopamine receptors.

Meyer JM, Ejendal KF, Avramova LV, Garland-Kuntz EE, Giraldo-Calderón GI, Brust TF, Watts VJ, Hill CA.

PLoS Negl Trop Dis. 2012 Jan;6(1):e1478. doi: 10.1371/journal.pntd.0001478. Epub 2012 Jan 24.

35.

Comparison of the D₁ dopamine full agonists, dihydrexidine and doxanthrine, in the 6-OHDA rat model of Parkinson's disease.

McCorvy JD, Watts VJ, Nichols DE.

Psychopharmacology (Berl). 2012 Jul;222(1):81-7. doi: 10.1007/s00213-011-2625-5. Epub 2012 Jan 6.

PMID:
22222862
36.

Analogues of doxanthrine reveal differences between the dopamine D1 receptor binding properties of chromanoisoquinolines and hexahydrobenzo[a]phenanthridines.

Cueva JP, Chemel BR, Juncosa JI Jr, Lill MA, Watts VJ, Nichols DE.

Eur J Med Chem. 2012 Feb;48:97-107. doi: 10.1016/j.ejmech.2011.11.039. Epub 2011 Dec 3.

37.

Assessment of dopamine D₁ receptor affinity and efficacy of three tetracyclic conformationally-restricted analogs of SKF38393.

Clark AH, McCorvy JD, Watts VJ, Nichols DE.

Bioorg Med Chem. 2011 Sep 15;19(18):5420-31. doi: 10.1016/j.bmc.2011.07.057. Epub 2011 Aug 3.

38.

Probing the steric space at the floor of the D1 dopamine receptor orthosteric binding domain: 7α-, 7β-, 8α-, and 8β-methyl substituted dihydrexidine analogues.

Cueva JP, Gallardo-Godoy A, Juncosa JI, Vidi PA, Lill MA, Watts VJ, Nichols DE.

J Med Chem. 2011 Aug 11;54(15):5508-21. doi: 10.1021/jm200334c. Epub 2011 Jul 14.

39.

Mapping the catechol binding site in dopamine D₁ receptors: synthesis and evaluation of two parallel series of bicyclic dopamine analogues.

Bonner LA, Laban U, Chemel BR, Juncosa JI, Lill MA, Watts VJ, Nichols DE.

ChemMedChem. 2011 Jun 6;6(6):1024-40. doi: 10.1002/cmdc.201100010. Epub 2011 Apr 28.

40.

Molecular and pharmacological characterization of two D(1)-like dopamine receptors in the Lyme disease vector, Ixodes scapularis.

Meyer JM, Ejendal KF, Watts VJ, Hill CA.

Insect Biochem Mol Biol. 2011 Aug;41(8):563-71. doi: 10.1016/j.ibmb.2011.03.008. Epub 2011 Mar 30.

PMID:
21457782
41.

Facile synthesis of octahydrobenzo[h]isoquinolines: novel and highly potent D1 dopamine agonists.

Bonner LA, Chemel BR, Watts VJ, Nichols DE.

Bioorg Med Chem. 2010 Sep 15;18(18):6763-70. doi: 10.1016/j.bmc.2010.07.052. Epub 2010 Jul 27.

42.

Fluorescent protein complementation assays: new tools to study G protein-coupled receptor oligomerization and GPCR-mediated signaling.

Vidi PA, Ejendal KF, Przybyla JA, Watts VJ.

Mol Cell Endocrinol. 2011 Jan 15;331(2):185-93. doi: 10.1016/j.mce.2010.07.011. Epub 2010 Jul 21. Review.

43.

Visualization of G protein-coupled receptor (GPCR) interactions in living cells using bimolecular fluorescence complementation (BiFC).

Vidi PA, Przybyla JA, Hu CD, Watts VJ.

Curr Protoc Neurosci. 2010 Apr;Chapter 5:Unit 5.29. doi: 10.1002/0471142301.ns0529s51.

44.

Ligand-induced regulation and localization of cannabinoid CB1 and dopamine D2L receptor heterodimers.

Przybyla JA, Watts VJ.

J Pharmacol Exp Ther. 2010 Mar;332(3):710-9. doi: 10.1124/jpet.109.162701. Epub 2009 Dec 16.

45.

The intracellular II-III loops of Cav1.2 and Cav1.3 uncouple L-type voltage-gated Ca2+ channels from glucagon-like peptide-1 potentiation of insulin secretion in INS-1 cells via displacement from lipid rafts.

Jacobo SM, Guerra ML, Jarrard RE, Przybyla JA, Liu G, Watts VJ, Hockerman GH.

J Pharmacol Exp Ther. 2009 Jul;330(1):283-93. doi: 10.1124/jpet.109.150672. Epub 2009 Apr 7.

46.

Fluorescent and bioluminescent protein-fragment complementation assays in the study of G protein-coupled receptor oligomerization and signaling.

Vidi PA, Watts VJ.

Mol Pharmacol. 2009 Apr;75(4):733-9. doi: 10.1124/mol.108.053819. Epub 2009 Jan 13. Review.

47.

Comparison of the enantiomers of (+/-)-doxanthrine, a high efficacy full dopamine D(1) receptor agonist, and a reversal of enantioselectivity at D(1) versus alpha(2C) adrenergic receptors.

Przybyla JA, Cueva JP, Chemel BR, Hsu KJ, Riese DJ 2nd, McCorvy JD, Chester JA, Nichols DE, Watts VJ.

Eur Neuropsychopharmacol. 2009 Feb;19(2):138-46. doi: 10.1016/j.euroneuro.2008.10.002. Epub 2008 Nov 22.

48.

Adenosine A(2A) receptors assemble into higher-order oligomers at the plasma membrane.

Vidi PA, Chen J, Irudayaraj JM, Watts VJ.

FEBS Lett. 2008 Dec 10;582(29):3985-90. doi: 10.1016/j.febslet.2008.09.062. Epub 2008 Nov 12.

49.

A point mutation to Galphai selectively blocks GoLoco motif binding: direct evidence for Galpha.GoLoco complexes in mitotic spindle dynamics.

Willard FS, Zheng Z, Guo J, Digby GJ, Kimple AJ, Conley JM, Johnston CA, Bosch D, Willard MD, Watts VJ, Lambert NA, Ikeda SR, Du Q, Siderovski DP.

J Biol Chem. 2008 Dec 26;283(52):36698-710. doi: 10.1074/jbc.M804936200. Epub 2008 Nov 4.

50.

Ligand-dependent oligomerization of dopamine D(2) and adenosine A(2A) receptors in living neuronal cells.

Vidi PA, Chemel BR, Hu CD, Watts VJ.

Mol Pharmacol. 2008 Sep;74(3):544-51. doi: 10.1124/mol.108.047472. Epub 2008 Jun 4.

PMID:
18524886

Supplemental Content

Loading ...
Support Center